Navigation Links
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Date:6/3/2008

fective in specifically suppressing VEGF production."

The Molecular Vision study can be accessed at http://www.molvis.org/molvis/v14/a119/

"Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes," NS Dejneka, S Wan, OS Bond, DJ Kornbrust, SJ Reich, Molecular Vision, Volume 14, May 28, 2008

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at http://www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential benefits and effectiveness of bevasiranib in suppressing the production of VEGF and reducing ocular neovascularization, our ability to establish OPKO's leadership position, our ability to aggressively engage in R&D activities and advance clinical testing of bevasiranib and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Man
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
2. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
3. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
4. Newly Approved HIV Drug Shows Great Promise
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/c8jldk/global_healthcare ) has announced the ... report to their offering. The Global ... and CRM BPO to grow at a CAGR of ... a segment of outsourcing, which consists of subcontracting the ... that has the expertise in the required domains. It ...
(Date:5/27/2015)... LOUIS , May 27, 2015   Mallinckrodt Pharmaceuticals ... will present on Wednesday, June 10, 2015, at the Goldman ... Resort in Rancho Palos Verdes, Calif. ... Mark Trudeau , President and Chief Executive Officer, and ... Investor Relations Officer, will represent the company in a session ...
(Date:5/27/2015)... ATLANTA , May 27, 2015  MT ... which operates lawsuitsettlementnews.com, reports today the most up-to-date ... including Stryker , DePuy, Wright, ... however, certain litigations are still dragging on and ... Stryker Corporation: Stryker Corporation has agreed to pay ...
Breaking Medicine Technology:Global Healthcare BPO Market 2015-2019 - Emergence of Cloud-based BPO in Healthcare with Accenture, Cognizant, Genpact, IBM, TCS, Wipro & Xerox Dominating 2Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference 2Major Hip Settlements Reported by Lawsuitsettlementnews.com 2Major Hip Settlements Reported by Lawsuitsettlementnews.com 3
... HERZELIYA, Israel, September 30 Medical device ... round led by 7 Health,Ventures. Previous investors: Ofer ... as well. , ActiViews, ... used,in Computer Tomography (CT), fluoroscopy and Magnetic Resonance ...
... , JERUSALEM, Israel, September 30 ... evaluating carlecortemcel-l, the generic,name of what is widely known ... leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo ... by,Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:5/27/2015)... Congratulations to all 50 winners of ... Award. From June 1, 2014 to June 1, 2015, ... alcohol addiction treatment centers around the country for their ... random at addiction treatment conferences throughout the past year. ... said, “Sky Toxicology would like to thank everyone for ...
(Date:5/27/2015)... Altec Products, Inc., a leader in enterprise ... Sponsorship of Connections 2015. The all-day client conference will ... 28th and will deliver to clients both the vision ... to get there. , Arxis Technology, Inc. is ... and support of Intacct Cloud Financials, Adaptive Insights, Sage ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Danish scientists ... line” biomarkers that have the potential to help in ... to read the full story that has just ... University in Aalborg, Denmark say new biomarkers found in ... outlook for patients with malignant mesothelioma . ...
(Date:5/27/2015)... Harbor, MD (PRWEB) May 27, 2015 ... will attend this year’s conference of the American Immigration ... at the Gaylord National Resort. MCA’s booth is #404. ... Annual Gathering in Immigration Law.” MCAads.com, a regular AILA ... family meeting” as they welcome current clients to their ...
(Date:5/27/2015)... 2015 With the FCPX LUT Cross ... quickly and easily add filmic color grades to their footage. ... , FCPX LUT Cross Processed Plugin can instantly make give ... and everything in between. , FCPX LUT Cross Processed Plugin ... many different softwares. With the FCPX LUT Cross Processed Loader ...
Breaking Medicine News(10 mins):Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 2Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 3Health News:Developers at Pixel Film Studios Release FCPX LUT Cross Processed Plugin for Final Cut Pro X 2
... MONDAY, May 9 (HealthDay News) -- Seniors can undergo weight-loss ... new research shows. "Age did not seem to be ... it did predict a longer period of hospital stay," said ... findings Monday at Digestive Diseases Week in Chicago. Research presented ...
... step in the processing of HIV within cells appears to ... recognize and destroy infected cells. Researchers at the Ragon ... as HIV proteins are broken down within cells, a process ... CD8 T cells there is a great variability in ...
... cancer whose disease has spread locally from inside ... treated with radiation therapy. However, disease recurs in ... the efficacy of this treatment and thereby decrease ... Shawn Lupold and colleagues, at Johns Hopkins University ...
... Stephen L. Boehm II, Ph.D., associate professor of psychology ... Indianapolis, has been named the 2011 Young Scientist of ... Society. The award will be presented May 13 at ... Boehm, a behavioral neuroscientist, is being honored for his ...
... Most strategies to assist the hungry, including food banks ... Program, are short-term, emergency solutions. Those who rely on ... foods, which lead to poor diet choices, nutritional deficiencies ... Missouri says the production of sustainable, locally grown foods ...
... 9 (HealthDay News) -- College athletes who play high-intensity ... greater risk for gastrointestinal disorders than other students and ... study, which was slated for presentation Sunday at the ... and female athletes and non-athletes. Researchers at Drexel ...
Cached Medicine News:Health News:Weight-Loss Surgery Seems No Riskier for Seniors 2Health News:Step in breakdown of HIV proteins essential to recognition, destruction of infected cells 2Health News:IUPUI behavioral neuroscientist receives international award for alcoholism research 2Health News:IUPUI behavioral neuroscientist receives international award for alcoholism research 3Health News:Availability of local food key to improving food security 2Health News:Some College Athletes More Prone to GI Disorders 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
Medicine Products: